10x Genomics, Inc. — Form 8-K Summary
Report date: June 10, 2021; the filing was signed June 15, 2021. The filing reports a material lease amendment and results from the company’s June 11, 2021 annual meeting of stockholders.
Business Context and Reporting Period
10x Genomics leases approximately 150,151 rentable square feet at 6230 Stoneridge Mall Road in Pleasanton, California. The company’s Class A common stock trades on Nasdaq under the symbol TXG.
Financial and Operating Metrics
- This 8-K does not provide revenue, profit, cash flow, margins, debt, liquidity, or other operating performance metrics.
- The company reported 289,806,395 eligible votes, representing approximately 92.74% of eligible voting power, present in person or by proxy at the annual meeting.
Material Changes and Corporate Actions
- On June 10, 2021, the company entered into the third amendment to its lease with 6200 Stoneridge Mall Road Investors LLC.
- The amendment addresses the allocation of certain building air-conditioning costs. The landlord agreed to upgrade specified air-conditioning controllers, with the related costs included in lease-defined operating expenses.
- Stockholders elected Kimberly J. Popovits and Bryan E. Roberts as Class II directors for three-year terms ending at the 2024 annual meeting, subject to earlier resignation, removal, or successor election.
- Stockholders ratified Ernst & Young LLP as the independent registered public accounting firm for fiscal year 2021.
- Stockholders voted in favor of holding future advisory votes on executive compensation annually. The board adopted a one-year frequency through the next required frequency vote, expected no later than the 2027 annual meeting.
Vote Results, Outlook, and Risks
| Proposal | Result |
|---|---|
| Election of Kimberly J. Popovits | 265,673,293 for; 13,599,200 against; 32,276 abstain; 10,501,626 broker non-votes |
| Election of Bryan E. Roberts | 264,777,496 for; 14,482,115 against; 45,158 abstain; 10,501,626 broker non-votes |
| Ratification of Ernst & Young LLP | 289,750,930 for; 18,971 against; 36,494 abstain; no broker non-votes |
| Advisory vote frequency for executive compensation | One year: 276,867,568; two years: 81,645; three years: 2,260,963; abstain: 94,593; broker non-votes: 10,501,626 |
The filing does not provide financial guidance or an earnings outlook. Investors should note that costs associated with the air-conditioning controller upgrades will be included in lease-defined operating expenses; the filing does not disclose the expected dollar amount or timing of those costs. The lease amendment’s complete terms are contained in Exhibit 10.1.
Key Facts to Verify
- Review Exhibit 10.1 for the full lease amendment, including the treatment and potential magnitude of air-conditioning-related operating expenses.
- Assess the company’s broader lease commitments and future occupancy costs in its periodic financial statements.
- Confirm the board’s implementation of annual advisory votes on executive compensation and monitor the next required frequency vote, expected by 2027.
- Review subsequent filings for any financial impact from the amended lease or changes in facility requirements.